22KIT
Better together
New data
shows Abbott's
FreeStyle Libre
Systems and
GLP-1 medicines
work better -
together - for
people with
Type 2 diabetes.
Data analyses show that
people with Type 2
diabetes (T2D) using GLP-1
medicines saw a significant
improvement in their HbA1c after
adding FreeStyle Libre technology
to their regimen. Better HbA1c
results were achieved irrespective
of GLP-1 duration, GLP-1 type, or
insulin therapy type. This shows that
FreeStyle Libre (FSL) systems help
people adhere to diabetes treatment
plans and support positive behaviour
changes by providing real-time data
that shows how food, activity and
medication can impact a person's
glucose levels
GLP-1 medicines - also known
as glucagon-like peptide-1 receptor
agonist (GLP-1 RA) - are increasingly
being prescribed for people with T2D
as they provide glycaemic benefit
and support weight loss. When blood
glucose levels start to rise after
someone eats, these drugs stimulate
the body to release more insulin,
which helps to lower blood glucose
levels. They also reduce appetite
leading to less food intake and weight
loss. Studies show that reaching and
maintaining a healthy body weight
can make diabetes more manageable.
Dr. Mahmood Kazemi, chief
medical officer for Abbott's
diabetes care business, "The data
analyses confirm that people using
GLP-1 medicines to manage their
diabetes can achieve even better
results when using it together with
FreeStyle Libre technology, This
type of complementary relationship
is not uncommon in diabetes care
treatment. Similar to pairing with
insulin therapy, FreeStyle Libre
technology is a beneficial companion
to GLP-1 therapy, providing the realtime data
that people with diabetes
can use to make positive behaviour
changes and navigate their GLP-1
usage safely."
Dr. Eden Miller, diabetologist and
obesity medicine fellow at Diabetes
and Obesity Care in Bend, Oregon,
adds, "GLP-1 medicines can be very
effective in lowering HbA1C for
people with Type 2 diabetes who
require intensified treatment. While
treating my patients, I've observed
that when we've added a CGM, like
the FreeStyle Libre technology,
to their GLP-1 therapy, we see
even better glycaemic control. To
maximise the benefits of GLP-1
medicines, it's worth considering the
combination of a CGM to support
people who live with Type 2 diabetes."
The FreeStyle Libre glucose
monitoring systems include a
sensor, which is applied to the back
of the upper arm for up to 14 days,
paired with a reader or compatible
smartphone app5 that displays
glucose readings. The Freestyle Libre
technology is the most widely used
CGM system worldwide6 helping
more than 5.5 million people living
across more than 60 countries7 to
easily monitor their glucose levels
www.freestylelibre.co.uk